The aim of our work was to dissect the molecular landscape of ZBTB16‐RARA AML, as compared to controls including a) classical APLs with PML‐RARA rearrangement, and b) other AMLs, in order to define biological differences sustaining the disease phenotype, and eventually identify “druggable” mutations. Here, RARA is linked to acute myeloid leukemia.